collection
https://read.qxmd.com/read/23871490/2-years-versus-1-year-of-adjuvant-trastuzumab-for-her2-positive-breast-cancer-hera-an-open-label-randomised-controlled-trial
#1
RANDOMIZED CONTROLLED TRIAL
Aron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, Evandro de Azambuja, Marion Procter, Thomas M Suter, Christian Jackisch, David Cameron, Harald A Weber, Dominik Heinzmann, Lissandra Dal Lago, Eleanor McFadden, Mitch Dowsett, Michael Untch, Luca Gianni, Richard Bell, Claus-Henning Köhne, Anita Vindevoghel, Michael Andersson, A Murray Brunt, Douglas Otero-Reyes, Santai Song, Ian Smith, Brian Leyland-Jones, Jose Baselga
BACKGROUND: Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial. METHODS: The HERA trial is an international, multicentre, randomised, open-label, phase 3 trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy, adjuvant chemotherapy, or both in 5102 patients with HER2-positive early breast cancer...
September 21, 2013: Lancet
https://read.qxmd.com/read/26099745/real-life-use-and-effectiveness-of-adjuvant-trastuzumab-in-early-breast-cancer-patients-a-study-of-the-southeast-netherlands-breast-cancer-consortium
#2
JOURNAL ARTICLE
Shanly C Seferina, Dorien J A Lobbezoo, Maaike de Boer, M Wouter Dercksen, Franchette van den Berkmortel, Roel J W van Kampen, Agnès J van de Wouw, Bart de Vries, Manuela A Joore, Petronella G M Peer, Adri C Voogd, Vivianne C G Tjan-Heijnen
BACKGROUND: The impact of drug prescriptions in real life as opposed to strict clinical trial prescription is only rarely assessed, although it is well recognized that incorrect use may harm patients and may have a significant impact on health care resources. We investigated the use and effectiveness of adjuvant trastuzumab in daily practice compared with the effectiveness in clinical trials. METHODS: We included all patients with stage I-III invasive breast cancer, irrespective of human epidermal growth factor receptor 2 (HER2) status, diagnosed in five hospitals in the southeast of The Netherlands in 2005-2007...
August 2015: Oncologist
https://read.qxmd.com/read/26077877/global-pricing-policies-and-cost-effectiveness-of-trastuzumab-in-latin-america
#3
EDITORIAL
Robert B Giffin
No abstract text is available yet for this article.
January 2015: International Journal of Technology Assessment in Health Care
https://read.qxmd.com/read/25693012/pertuzumab-trastuzumab-and-docetaxel-in-her2-positive-metastatic-breast-cancer
#4
RANDOMIZED CONTROLLED TRIAL
Sandra M Swain, José Baselga, Sung-Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiss, Sarah Heeson, Emma Clark, Graham Ross, Mark C Benyunes, Javier Cortés
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months...
February 19, 2015: New England Journal of Medicine
https://read.qxmd.com/read/26047983/targeting-her2-with-t-dm1-an-antibody-cytotoxic-drug-conjugate-is-effective-in-her2-over-expressing-bladder-cancer
#5
COMPARATIVE STUDY
Tetsutaro Hayashi, Roland Seiler, Htoo Zarni Oo, Wolfgang Jäger, Igor Moskalev, Shannon Awrey, Takashi Dejima, Tilman Todenhöfer, Na Li, Ladan Fazli, Akio Matsubara, Peter C Black
PURPOSE: Systemic therapy for advanced bladder cancer has not changed substantially in more than 2 decades and mortality rates remain high. The recognition of HER2 over expression in bladder cancer has made HER2 a promising therapeutic target. T-DM1, a new drug consisting of the HER2 antibody trastuzumab conjugated with a cytotoxic agent, has been shown in breast cancer to be superior to trastuzumab. We tested T-DM1 in preclinical models of bladder cancer. MATERIALS AND METHODS: We evaluated the effect of T-DM1 compared to trastuzumab in different in vitro and in vivo models of HER2 over expressing bladder cancer...
October 2015: Journal of Urology
https://read.qxmd.com/read/26048264/does-diastolic-dysfunction-precede-systolic-dysfunction-in-trastuzumab-induced-cardiotoxicity-assessment-with-multigated-radionuclide-angiography-muga
#6
JOURNAL ARTICLE
E J Reuvekamp, B F Bulten, A A Nieuwenhuis, M R A Meekes, A F J de Haan, J Tol, A H E M Maas, S E Elias-Smale, L F de Geus-Oei
BACKGROUND: Trastuzumab is successfully used for the treatment of HER2-positive breast cancer. Because of its association with cardiotoxicity, LVEF is monitored by MUGA, though this is a relatively late measure of cardiac function. Diastolic dysfunction (DD) is believed to be an early predictor of cardiac impairment. We evaluate the merit of MUGA-derived diastolic function parameters in the early detection of trastuzumab-induced cardiotoxicity (TIC). METHODS AND RESULTS: 77 trastuzumab-treated patients with normal baseline systolic and diastolic function were retrospectively selected (n = 77)...
August 2016: Journal of Nuclear Cardiology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.